Cuban Biotech Drug Jusvinza Shows Promising Results in Autoimmune Diseases and Viral Infections

Developed by Cuba’s Center for Genetic Engineering and Biotechnology (CIGB), the biopharmaceutical Jusvinza has demonstrated efficacy in treating rheumatoid arthritis, severe cases of COVID-19, and post-chikungunya complications, according to clinical trials and medical experts.

Targeting Autoimmune Conditions: Rheumatoid Arthritis

Jusvinza, designed to modulate the immune system, has advanced through Phase I and II clinical trials for rheumatoid arthritis, an autoimmune disorder where the immune system attacks joint tissues. Dr. María del Carmen Domínguez, lead scientist at CIGB, explained the drug’s mechanism: “It reeducates the immune system to stop attacking the body’s own tissues, offering a targeted approach compared to traditional immunosuppressants.”

A case study highlighted by the CIGB involved a nurse with severe rheumatoid arthritis who regained mobility after four months of treatment, enabling her to dance with her child. The drug received conditional approval in Cuba in 2023 for use in rheumatology clinics, pending completion of Phase III trials.

Combatting Severe COVID-19 Cases

During the COVID-19 pandemic, Jusvinza was integrated into treatment protocols for critically ill patients. Julio Baldomero Hernández, director of clinical research at CIGB, noted: “It achieved an 85% survival rate in intensive care settings, particularly for patients with hyperinflammatory responses.” The drug was included in Cuba’s Ministry of Public Health guidelines, alongside antivirals and oxygen therapy.

Unlike conventional immunosuppressants, Jusvinza does not weaken the immune system, allowing complementary therapies to function more effectively. This characteristic has drawn interest from international health organizations.

Addressing Chikungunya Sequelae

Chikungunya, a viral infection causing joint pain and inflammation, has seen limited treatment options. Jusvinza’s application for post-chikungunya arthritis showed “85% improvement in patients after 45 days,” according to CIGB trials. A study in Havana and Matanzas—where the virus first emerged in Cuba—reported a 94% improvement rate at 12 weeks, surpassing traditional treatments like corticosteroids, which often led to relapses.

Dr. Domínguez emphasized the drug’s potential: “It addresses both symptoms and underlying inflammation, offering a longer-term solution for chronic cases.”

Global Interest and Future Research

Several countries are collaborating with Cuba to analyze Jusvinza’s protocols, particularly for respiratory conditions. CIGB is currently finalizing Phase III trials for severe pneumonia and respiratory distress, with preliminary data showing “high survival rates” in clinical settings.

While the drug remains primarily available in Cuba, its biotech innovations have sparked discussions about its potential for global health challenges. Hernández stated, “Jusvinza represents a novel approach to immune modulation, with applications beyond its current indications.”

Sources: CIGB Official Website, Cuban Ministry of Public Health